Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini M, Song J, Yun S, Talati C, Kuykendall A, Padron E, Walker A, Roboz G, Desai P, Sallman D, Sweet K, Komrokji R, Lancet J.
Chan O, et al. Among authors: ball s.
Blood Adv. 2024 Mar 12;8(5):1075-1083. doi: 10.1182/bloodadvances.2023011173.
Blood Adv. 2024.
PMID: 38170740
Free PMC article.